1.	A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women Phase: Phase III Type: Prevention Status: Closed Age: 24 to 45 Sponsor: Pharmaceutical / Industry Protocol IDs: 2004_013, V501-019, NCT00090220
2.	Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents Phase: Phase III Type: Prevention Status: Completed Age: 11 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: 2005_092, V501-025, NCT00325130
3.	Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 11 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: 2005_093, V501-024, NCT00337428
4.	Immunogenicity of GSK Bio's HPV Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 to 45 Sponsor: Pharmaceutical / Industry Protocol IDs: 108933, NCT00423046
5.	Safety, Tolerability and Immunogenicity of HPV Vaccine in Healthy Females 9 to 15 Years of Age in India. Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 9 to 15 Sponsor: Pharmaceutical / Industry Protocol IDs: 2006_038, V501-029, NCT00380367
6.	An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Closed Age: 9 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: 2007_021, V501-030, NCT00496626
7.	A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 9 to 26 Sponsor: Other Protocol IDs: H07-00928, BCGov-01, NCT00501137
8.	Broad Spectrum HPV Vaccine Dose Ranging Study Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 16 to 23 Sponsor: Pharmaceutical / Industry Protocol IDs: 2005_086, V502-001, NCT00260039
9.	V501 (Gardasil) Study in Preadolescent Females Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Closed Age: 9 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: 2006_052, V501-028, NCT00411749
10.	Phase II Pilot Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine in Male Patients With HIV-1 Infection Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: AMC-052, 052, NCT00513526
11.	Broad Spectrum HPV (Human Papillomavirus) Vaccine (V505) in 16 to 26 Year Old Women Phase: Phase II Type: Prevention Status: Closed Age: 16 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: 2007_567, V505-001, NCT00520598
12.	A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL Phase: Phase II Type: Prevention Status: Closed Age: 16 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: 2007_566, V504-001, NCT00551187
13.	Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities Phase: No phase specified Type: Natural history/Epidemiology, Prevention Status: Enrolling by invitation Age: 18 to 26 Sponsor: Other Protocol IDs: DDEAMC 07-43X, NCT00501189